Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 60

1.

Clinical and Patient-Related Variables Associated with Initiating GLP-1 Receptor Agonist Therapy in Type 2 Diabetes Patients in Primary Care in Germany.

Qiao Q, Grandy S, Hiller J, Kostev K.

PLoS One. 2016 Mar 28;11(3):e0152281. doi: 10.1371/journal.pone.0152281. eCollection 2016.

2.

A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus.

Kayaniyil S, Lozano-Ortega G, Bennett HA, Johnsson K, Shaunik A, Grandy S, Kartman B.

Diabetes Ther. 2016 Mar;7(1):27-43. doi: 10.1007/s13300-016-0155-1. Epub 2016 Feb 17. Review.

3.

Patient-reported outcomes among patients with type 2 diabetes mellitus treated with dapagliflozin in a triple-therapy regimen for 52 weeks.

Grandy S, Sternhufvud C, Ryden A, Sugg J, Rohwedder K.

Diabetes Obes Metab. 2016 Mar;18(3):306-9. doi: 10.1111/dom.12604. Epub 2016 Jan 5.

PMID:
26537439
4.

Cost-Effectiveness Analysis of Exenatide Once-Weekly Versus Dulaglutide, Liraglutide and Lixisenatide for the Treatment of Type 2 Diabetes Mellitus: An Analysis from the UK NHS Perspective.

Charokopou M, Chuang L, Verheggen B, Gibson D, Grandy S, Kartman B.

Value Health. 2015 Nov;18(7):A606. doi: 10.1016/j.jval.2015.09.2090. Epub 2015 Oct 20. No abstract available.

PMID:
26533406
5.

Pharmacy Cost Differences Associated with the Initiation of Exenatide Once-Weekly Compared to Liraglutide Once-Daily.

Loughlin AM, Qiao Q, Grandy S, Yochum LA, Clifford CR, Dore DD.

Value Health. 2015 Nov;18(7):A602. doi: 10.1016/j.jval.2015.09.2068. Epub 2015 Oct 20. No abstract available.

PMID:
26533382
6.

Exenatide Once Weekly Plus Metformin for the Treatment of Type 2 Diabetes Mellitus: A Network Meta-Analysis of Randomised Controlled Trials.

Kayaniyil S, Lozano-Ortega G, Bennett H, Johnsson K, Shaunik A, Grandy S, Kartman B.

Value Health. 2015 Nov;18(7):A597-8. doi: 10.1016/j.jval.2015.09.2044. Epub 2015 Oct 20. No abstract available.

PMID:
26533352
7.

Cardiovascular event rates and healthcare resource utilisation among high-risk adults with type 2 diabetes mellitus in a large population-based study.

Fox KM, Wu Y, Kim J, Grandy S.

Int J Clin Pract. 2015 Feb;69(2):218-27. doi: 10.1111/ijcp.12530.

PMID:
25627336
8.

Patient Characteristics are not Associated with Clinically Important Differential Response to Dapagliflozin: a Staged Analysis of Phase 3 Data.

Bujac S, Del Parigi A, Sugg J, Grandy S, Liptrot T, Karpefors M, Chamberlain C, Boothman AM.

Diabetes Ther. 2014 Dec;5(2):471-82. doi: 10.1007/s13300-014-0090-y. Epub 2014 Dec 12.

9.

Health-related quality of life (EQ-5D) among type 2 diabetes mellitus patients treated with dapagliflozin over 2 years.

Grandy S, Langkilde AM, Sugg JE, Parikh S, Sjöström CD.

Int J Clin Pract. 2014 Apr;68(4):486-94. doi: 10.1111/ijcp.12341. Epub 2014 Feb 6.

PMID:
24499168
10.
11.

Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin.

Grandy S, Hashemi M, Langkilde AM, Parikh S, Sjöström CD.

Diabetes Obes Metab. 2014 Jul;16(7):645-50. doi: 10.1111/dom.12263. Epub 2014 Feb 9.

PMID:
24443876
12.

Health-related quality of life association with weight change in type 2 diabetes mellitus: perception vs. reality.

Grandy S, Fox KM, Bazata DD; SHIELD Study Group.

Int J Clin Pract. 2013 May;67(5):455-61. doi: 10.1111/ijcp.12093.

PMID:
23574105
13.

Change in health status (EQ-5D) over 5 years among individuals with and without type 2 diabetes mellitus in the SHIELD longitudinal study.

Grandy S, Fox KM; SHIELD Study Group.

Health Qual Life Outcomes. 2012 Aug 21;10:99. doi: 10.1186/1477-7525-10-99.

14.
15.

Rate and risk predictors for development of self-reported type-2 diabetes mellitus over a 5-year period: the SHIELD study.

Rodbard HW, Bays HE, Gavin JR 3rd, Green AJ, Bazata DD, Lewis SJ, Fox KM, Reed ML, Grandy S.

Int J Clin Pract. 2012 Jul;66(7):684-91. doi: 10.1111/j.1742-1241.2012.02952.x.

PMID:
22698420
16.
17.

Self-reported hypoglycemia and impact on quality of life and depression among adults with type 2 diabetes mellitus.

Green AJ, Fox KM, Grandy S; SHIELD Study Group.

Diabetes Res Clin Pract. 2012 Jun;96(3):313-8. doi: 10.1016/j.diabres.2012.01.002. Epub 2012 Jan 31.

PMID:
22296853
18.

Overexpression of type 1 angiotensin II receptors impairs excitation-contraction coupling in the mouse heart.

Rivard K, Grandy SA, Douillette A, Paradis P, Nemer M, Allen BG, Fiset C.

Am J Physiol Heart Circ Physiol. 2011 Nov;301(5):H2018-27. doi: 10.1152/ajpheart.01092.2010. Epub 2011 Aug 19.

19.
20.

Impact of Regular Exercise and Attempted Weight Loss on Quality of Life among Adults with and without Type 2 Diabetes Mellitus.

Green AJ, Fox KM, Grandy S.

J Obes. 2011;2011. pii: 172073. doi: 10.1155/2011/172073. Epub 2010 Sep 23.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk